This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McDermott, D. F. Articles by Hersh, E. Search for Related Content PubMed PubMed Citation Articles by McDermott, D. F. Articles by Hersh, E. Social Bookmarking                            What's this?

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

David F. McDermott, Jeffrey A. Sosman, Rene Gonzalez, F. Stephen Hodi, Gerald P. Linette, Jon Richards, James W. Jakub, Muralidhar Beeram, Stefano Tarantolo, Sanjiv Agarwala, Gary Frenette, Igor Puzanov, Lee Cranmer, Karl Lewis, John Kirkwood, J. Michael White, Chenghua Xia, Kiran Patel, Evan Hersh

From the Beth Israel Deaconess Medical Center; Dana Farber Cancer Institute, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Colorado Health Sciences Center, Aurora, CO; Washington University School of Medicine, St Louis, MO; Lutheran General Cancer Care Center, Park Ridge, IL; Lakeland Regional Cancer Center, Lakeland, FL; University of Texas Health Science Center, San Antonio, TX; Nebraska Methodist Hospital, Omaha, NB; St Luke's Health System, Bethlehem; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Carolinas Hematology-Oncology Associates, Charlotte, NC; University of Arizona Cancer Center, Tucson AZ; Onyx Pharmaceuticals, Inc, Emeryville, CA; and Bayer HealthCare Pharmaceuticals, West Haven, CT

Corresponding author: David F. McDermott, MD, Clinical Director of Biologic Therapy Program, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, East KS-159, Boston, MA; e-mail: dmcdermo{at}bidmc.harvard.edu

Purpose This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma.

Patients and Methods This randomized, double-blind, placebo-controlled, multicenter study enrolled chemotherapy-naïve patients with stage III (unresectable) or IV melanoma. A total of 101 patients received placebo plus dacarbazine (n = 50) or sorafenib plus dacarbazine (n = 51). On day 1 of a 21-day cycle, patients received intravenous dacarbazine 1,000 mg/m² for a maximum of 16 cycles. Oral sorafenib 400 mg or placebo was administered twice a day continuously. The primary end point was progression-free survival (PFS) by independent assessment. Secondary and tertiary end points included time to progression (TTP), response rate, and overall survival (OS).

Results Median PFS in the sorafenib plus dacarbazine arm was 21.1 weeks versus 11.7 weeks in the placebo plus dacarbazine arm (hazard ratio [HR], 0.665; P = .068). There were statistically significant improvements in PFS rates at 6 and 9 months, and in TTP (median, 21.1 v 11.7 weeks; HR, 0.619) in favor of the sorafenib plus dacarbazine arm. No difference in OS was observed (median, 51.3 v 45.6 weeks in the placebo plus dacarbazine and sorafenib plus dacarbazine arms, respectively; HR, 1.022). The regimen was well tolerated and had a manageable toxicity profile.

Conclusion Sorafenib plus dacarbazine was well tolerated in patients with advanced melanoma and yielded an encouraging improvement in PFS. Based on these findings, additional studies with the combination are warranted in this patient population.

Supported by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc.

Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2007 and at the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Hauschild, S. S. Agarwala, U. Trefzer, D. Hogg, C. Robert, P. Hersey, A. Eggermont, S. Grabbe, R. Gonzalez, J. Gille, et al. Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma J. Clin. Oncol., June 10, 2009; 27(17): 2823 - 2830. [Abstract] [Full Text] [PDF]

				M.-S. VUORISTO, P. VIHINEN, T. SKYTTA, K. TYYNELA, and P. KELLOKUMPU-LEHTINEN Carboplatin and Vinorelbine Combined with Subcutaneous Interleukin-2 in Metastatic Melanoma with Poor Prognosis Anticancer Res, May 1, 2009; 29(5): 1755 - 1759. [Abstract] [Full Text] [PDF]

				I. D. Davis, B. Brady, R. F. Kefford, M. Millward, J. Cebon, B. K. Skrumsager, U. Mouritzen, L. T. Hansen, K. Skak, D. Lundsgaard, et al. Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial Clin. Cancer Res., March 15, 2009; 15(6): 2123 - 2129. [Abstract] [Full Text] [PDF]

				J. Yang, S. Zaja-Milatovic, Y.-M. Thu, F. Lee, R. Smykla, and A. Richmond Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy Mol. Cancer Ther., March 1, 2009; 8(3): 636 - 647. [Abstract] [Full Text] [PDF]

				A. Sharma, A. K. Sharma, S. V. Madhunapantula, D. Desai, S. J. Huh, P. Mosca, S. Amin, and G. P. Robertson Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates Clin. Cancer Res., March 1, 2009; 15(5): 1674 - 1685. [Abstract] [Full Text] [PDF]

				E. Winer, J. Gralow, L. Diller, B. Karlan, P. Loehrer, L. Pierce, G. Demetri, P. Ganz, B. Kramer, M. Kris, et al. Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening--A Report From the American Society of Clinical Oncology J. Clin. Oncol., February 10, 2009; 27(5): 812 - 826. [Abstract] [Full Text] [PDF]

				L. Jilaveanu, C. Zito, S. J. Lee, K. L. Nathanson, R. L. Camp, D. L. Rimm, K. T. Flaherty, and H. M. Kluger Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib Clin. Cancer Res., February 1, 2009; 15(3): 1076 - 1085. [Abstract] [Full Text] [PDF]

				J. Poust Targeting metastatic melanoma Am. J. Health Syst. Pharm., December 15, 2008; 65(24_Supplement_9): S9 - S15. [Abstract] [Full Text] [PDF]

				D. Tyler Regional Therapeutic Strategies in Melanoma: Not Just Local Disease Control, but an Opportunity to Develop Novel Therapeutic Strategies with Potential Implications for Systemic Therapy Ann. Surg. Oncol., November 1, 2008; 15(11): 2987 - 2990. [Full Text] [PDF]